https://www.labiotech.eu/trends-news/akt-inhibitor-shows-effective-patienttrial/
0
0
10/28/22 at 10:20am
Organization
Labiotech.eu
Author
Jim Cornall
27 words
0
Comments
In a trial 22% of cancer patients treated with AKT inhibitor ipatasertib had their tumors shrink.
You are the first to view
Create an account
or login to join the discussion